Manufacturer presents new Phase III data for faricimab in the treatment of diabetic macular oedema and neovascular age-related macular degeneration

Over four Phase III studies (YOSEMITE, RHINE, TENAYA, LUCERNE), the investigational bispecific antibody was non-inferior to aflibercept in terms of vision gains, and approx half of patients eligible for extended dosing were able to be treated every 4 months in the first year

Source:

Biospace Inc.